• Relapsed AML with NPM1 mutation is genetically related to the primary leukemia and characterized by an increase in high risk aberrations.
Introduction
Acute myeloid leukemia (AML) is a clonal disease that is characterized by the presence of a variety of genetic alterations. Mutations in the nucleophosmin (NPM1) gene represent one of the most common gene mutations (25% to 30%) in AML. 1 Approximately 85% of AML with NPM1 mutation (NPM1 mut ) display a cytogenetically normal (CN) karyotype if determined by chromosome banding analysis. High-resolution techniques like single-nucleotide polymorphism (SNP) arrays revealed only a few submicroscopic copy-number alterations (CNA) in NPM1 mut AML, whereas uniparental disomies (UPD) that result in loss of heterozygosity (LOH) were detected in 10% to 20% of the patients. 2, 3 NPM1 mut co-occurs with known AML-associated mutations like FLT3, DNMT3A, IDH1, IDH2 and NRAS. 1, [4] [5] [6] [7] These mutations seem not to accumulate in a random order but instead can be allocated to early and late events in the transformation process from a normal hematopoietic stem (HSC) or progenitor cell to leukemia. 8, 9 A high proportion of NPM1 mut AML patients achieve complete remission (CR) with intensive chemotherapy; however, approximately 50% of these patients experience relapse during the first 3 years after diagnosis, in particular patients with concurrent internal tandem duplications (ITD) of the FLT3 gene. 1, [10] [11] [12] Relapse is generally less responsive to chemotherapy and a major cause of death in patients with AML. Other characteristics of NPM1 mut AML include low expression or absence of the hematopoietic cell surface marker CD34, multilineage involvement as well as a unique geneexpression and miRNA signature. 13 Based on these clinical and biological characteristics, NPM1 mut AML was included as a provisional entity in the current WHO classification. 14 Besides the distinct properties of NPM1 mut AML, NPM1 mut is considered as a founder event in the pathogenesis of AML, mainly based on the observation that the mutation is stable over time and in general maintained at relapse, even occurring after a long latency. 15, 16 However, we and other groups observed loss of NPM1 mut in ~10% of relapsed patients and this loss was generally accompanied by further chromosomal and molecular changes. [17] [18] [19] To date, it is still unclear whether these cases can be explained by clonal evolution from a common pre-leukemic ancestor or if these patients developed therapy-related AML (t-AML) that evolved from an independent hematopoietic HSC or progenitor cell. In order to assess clonal evolution in the genetically defined subgroup "AML with
NPM1
mut ", we analyzed paired leukemia samples obtained at the time of diagnosis and relapse from 53 NPM1 mut AML patients by using high-resolution SNP array profiling and mutation analysis of 10 AML-associated genes.
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Methods

Patients
Patient characteristics for the fifty-three adult AML patients (age 24 to 66 years) are given in Table 1 . All patients gave informed consent for both treatment and genetic analysis according to the Declaration of Helsinki. Approval was obtained from the Institutional Review Boards of the participating AMLSG institutions.
Single-nucleotide polymorphism (SNP) microarray-based genotyping analysis
SNP profiling was performed as described recently 3, 30 ; details are provided in the Supplement. Microarray raw data were made publicly available at NCBI's Gene Expression Omnibus (GEO-accession number: GSE46951). Tables 1 and 2) Taken together, we identified one CNA or UPD in 11 patients (21%) and 2 aberrations in 2 patients (4%) at diagnosis ( Figure 1 , Table 2 ) with del(9q) and UPD13q being the only recurrent aberrations.
Further methods are described in the Supplement.
Results
Cytogenetics
At the time of relapse: At relapse, cytogenetic analysis was available for 14 patients and revealed a normal karyotype in 6 patients (all with a normal karyotype at diagnosis) and an aberrant karyotype in 8 patients (6 with normal karyotype, 2 with no available metaphases at diagnosis, respectively)(Supplementary Table 3 Table 2, Supplementary Table 1+2 ).
The majority of the altered genomic regions at relapse (76%) were exclusively affected in relapse samples. CNAs in these regions could neither be detected in the 53
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Two of the 5 patients with UPD at diagnosis lost UPD at relapse (UPD13q in UPN#23
and UPD1p in UPN#1). Conversely, 7 patients acquired a new UPD13q with homozygous FLT3-ITD mutation at relapse (5 with heterozygous and 2 without FLT3-ITD mutation at diagnosis)( Figure 2B ).
Gene mutation pattern at diagnosis and relapse
At the time of diagnosis, we observed a typical pattern for concurrent gene mutations in NPM1 mut AML ( Figure 3 and ASXL1 mutations do not seem to play a major role since only one TP53 and two ASXL1 mutations were detected at this time point.
The limited sensitivity (~5%) of the techniques used in this study did not allow us to determine whether newly acquired mutations or genomic alterations at relapse already pre-existed in small subclones at the time of diagnosis or whether they were acquired during or after chemotherapy. Deep sequencing of 8 paired diagnosis/relapse AML samples by Ding et al. could not detect the majority of the relapse-specific mutations in the primary AML sample suggesting that these mutations were acquired after therapy. 32 However, even high-coverage targeted sequencing has a detection limit of ~ 2% and therefore will not allow to detect very small sublcones that expand under selection pressure with chemotherapy. We also cannot rule out the possibility that distinct mutations, in particular frequent ones like NPM1 mutation type A, were lost and reacquired at relapse. Within this context, one patient showed different NRAS mutation types at diagnosis and relapse, indicating that this is a possible mechanism of clonal evolution. Similarly, 3 of 24 patients showed different FLT3-ITD clones at relapse.
However, this was not the case for DNMT3A mut where all patients maintained the same nucleotide changes.
Loss of NPM1 mut has been described to occur in ~10% of relapsed AML. [17] [18] [19] Because of the long latency between primary leukemia and relapse, together with a diverging pattern of genomic alterations and gene mutations, these cases were initially interpreted as therapy-related AML (t-AML) rather than relapse. 17, 18 Extending the number of analyzed genes in these patients, we consistently found DNMT3A mut in the primary and relapse sample in 5 out of 5 NPM1 mut loss cases. For each patient, we found the same nucleotide changes in DNMT3A, making it more likely that a common ancestral DNMT3A mut but NPM1 wildtype clone gave rise to both primary and relapsed AML as opposed to a scenario where two hematopoietic clones have independently acquired the same DNMT3A mut . The observation that at least in these 5 cases DNMT3A mut most likely preceded NPM1 mut controverts the current concept that NPM1 mut is generally the founder event in NPM1 mut AML. 13 However, one case in our cohort lost DNMT3A mut at relapse and maintained NPM1 mut highlighting that the sequential order in which they occur is not strictly determined. DNMT3A knockout in mouse hematopoietic stem cells strongly induces self-renewal, supporting its role in malignant transformation. 41 However, even after several rounds of transplantation these mice do not develop AML or other myeloid malignancies, suggesting the need for secondary genetic hits. This might explain the long latency between the primary leukemia and relapse observed in the 5 patients with In our study, combined SNP-array profiling and mutational analysis revealed that all 53 relapses shared at least one mutation or aberration with their matched primary sample, implicating a common cell of origin. Based on our findings, there is no evidence for t-AML that derived from a genetically unrelated hematopoietic clone. Similarly, previous combined genomic and molecular studies in AML 31, 32 and acute lymphoblastic leukemia 42, 43 have demonstrated that the primary leukemia and relapse in general are genetically related and derive directly from the dominant leukemic clone or from a common ancestral clone. In addition, the increase of specific genomic aberrations that we found in our NPM1 mut cohort at the time of relapse suggests that DNA-damaging chemotherapy causes secondary genetic changes in persisting (pre-)leukemic clones. In this respect, some of the specific alterations we found exclusively at relapse, such as -7/del(7q) and der(12;17))(q10;q10), are frequent in patients that were previously treated with chemotherapy. 44 This hypothesis is further supported by the whole-genome sequencing study that revealed a marked increase in the absolute number of a specific type of mutation (transversions) in the genomes of relapsed AML compared to de novo AML. 32 In our study, 26 of the 53 relapses (49%) evolved directly from the dominant primary clone as it maintained all the mutations and genomic aberrations present in the primary AML sample. The other group of 27 (51%) relapse samples lost some of the genetic changes of the initial clone but shared at least one common genetic alteration implying that they derived from an ancestral clone. Although limited by the markers studied, our data is in line with data from a whole-genome sequencing study in relapsed AML where 3 out of 8 relapses evolved from the dominant primary clone and the remaining 5 from a minor, genetically related subclone. 32 Genetic characterization of FACS-sorted HSCs and leukemic stem cells of AML patient samples directly demonstrated that these (pre-)leukemic subclones that comprise some but not all mutations (mostly FLT3-ITD) coexist with the dominant leukemic clone at diagnosis. 40 In conclusion, while NPM1 mut is generally considered as a primary event in NPM1 mut AML our data suggest that mutations in DNMT3A can precede NPM1 mutations. Even after a long latency of up to 110 months, all relapses were genetically related to the initial AML suggesting that persisting subclones or preleukemic HSCs acquire new secondary aberrations rather than being genetically unrelated t-AML. In order to achieve long-term leukemia-free survival, future therapies in AML need to eradicate all (pre-)leukemic clones present at diagnosis that persist during therapy and contribute to relapse. 
